Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.
Retrospective Data Shed Light on Prognostic Value of PD-L1 Expression in Metastatic Papillary RCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
TIBs Linked With Poor Outcomes With Anti–PD-1 Therapy Plus Axitinib in Metastatic ccRCC
FDA Approval Insights: Ponatinib in Ph+ ALL
First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors
OncLive’s April Roundup of Key FDA Decisions in Oncology
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth
HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies